Aabø-Evensen & Co acted as legal advisor to Lytix Biopharma AS in connection with a NOK 80 million private placement

The new funding enables the company to continue the development of the company’s cancer immunotherapy project LTX-315 through 2016.

- We are very pleased that new and existing investors share our confidence in the potential for the oncolytic peptide LTX-315 in the rapidly advancing field of immunotherapy. With this new funding in place, we aim to initiate combination trials in order to generate new valuable data, says Lytix Biopharma CEO Unni Hjelmaas.

To be redirected to Lytix Biopharma's press release, please click here